Sökning: onr:"swepub:oai:DiVA.org:umu-209194" >
Measurable residual...
-
van Weelderen, Romy E.Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
(författare)
Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia : a study by the international Berlin-Frankfurt-Münster study group
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
-
American Society of Clinical Oncology (ASCO),2023
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:umu-209194
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-209194URI
-
https://doi.org/10.1200/JCO.22.02120DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Purpose: A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value of flow cytometry-based measurable residual disease (flow-MRD) and evaluated the benefit of allogeneic stem-cell transplantation (allo-SCT) in first complete remission (CR1) in this disease.Methods: A total of 1,130 children with KMT2A-r AML, diagnosed between January 2005 and December 2016, were assigned to high-risk (n = 402; 35.6%) or non-high-risk (n = 728; 64.4%) fusion partner-based groups. Flow-MRD levels at both end of induction 1 (EOI1) and 2 (EOI2) were available for 456 patients and were considered negative (<0.1%) or positive (≥0.1%). End points were 5-year event-free survival (EFS), cumulative incidence of relapse (CIR), and overall survival (OS).Results: The high-risk group had inferior EFS (30.3% high risk v 54.0% non-high risk; P < .0001), CIR (59.7% v 35.2%; P < .0001), and OS (49.2% v 70.5%; P < .0001). EOI2 MRD negativity was associated with superior EFS (n = 413; 47.6% MRD negativity v n = 43; 16.3% MRD positivity; P < .0001) and OS (n = 413; 66.0% v n = 43; 27.9%; P < .0001), and showed a trend toward lower CIR (n = 392; 46.1% v n = 26; 65.4%; P = .016). Similar results were obtained for patients with EOI2 MRD negativity within both risk groups, except that within the non-high-risk group, CIR was comparable with that of patients with EOI2 MRD positivity. Allo-SCT in CR1 only reduced CIR (hazard ratio, 0.5 [95% CI, 0.4 to 0.8]; P = .00096) within the high-risk group but did not improve OS. In multivariable analyses, EOI2 MRD positivity and high-risk group were independently associated with inferior EFS, CIR, and OS.Conclusion: EOI2 flow-MRD is an independent prognostic factor and should be included as risk stratification factor in childhood KMT2A-r AML. Treatment approaches other than allo-SCT in CR1 are needed to improve prognosis.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Klein, KimPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, Netherlands
(författare)
-
Harrison, Christine J.Leukemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom
(författare)
-
Jiang, YilinPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
(författare)
-
Abrahamsson, JonasDepartment of Pediatrics, Institute of Clinical Sciences, Salgrenska University Hospital, Gothenburg, Sweden
(författare)
-
Arad-Cohen, NiraPediatric Hemato-Oncology Department, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel
(författare)
-
Bart-Delabesse, EmmanuelleIUC Toulouse-Oncopole, Laboratoire d'Hématologie secteur Génétique des Hémopathies, Toulouse, France
(författare)
-
Buldini, BarbaraPediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padua University, Padua, Italy
(författare)
-
De Moerloose, BarbaraDepartment of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
(författare)
-
Dworzak, Michael N.St. Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, St Anna Children's Cancer Research Institute, Vienna, Austria
(författare)
-
Elitzur, SarahDepartment of Pediatric Hematology and Oncology, Schneider Children's Medical Center and Tel Aviv University, Tel Aviv, Israel
(författare)
-
Fernández Navarro, José MPediatric Oncohematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain
(författare)
-
Gerbing, Robert B.Department of Statistics, Children's Oncology Group, CA, Monrovia, United States
(författare)
-
Goemans, Bianca F.Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
(författare)
-
de Groot-Kruseman, Hester A.Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; DCOG, Dutch Childhood Oncology Group, Utrecht, Netherlands
(författare)
-
Guest, ErinChildren's Mercy Kansas City, MO, Kansas City, United States
(författare)
-
Ha, Shau-YinDepartment of Pediatrics & Adolescent Medicine, Hong Kong Children's Hospital, Kowloon, Hong Kong
(författare)
-
Hasle, HenrikPediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
(författare)
-
Kelaidi, CharikleiaDepartment of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece
(författare)
-
Lapillonne, HélènePediatric Hematology and Oncology Department, Hôpital Armand Trousseau, Paris, France
(författare)
-
Leverger, GuyPediatric Hematology and Oncology Department, Hôpital Armand Trousseau, Paris, France
(författare)
-
Locatelli, FrancoDepartment of Pediatric Hematology and Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy
(författare)
-
Masetti, RiccardoPediatric Oncology and Hematology, University of Bologna, Bologna, Italy
(författare)
-
Miyamura, TakakoDepartment of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
(författare)
-
Norén-Nyström, UlrikaUmeå universitet,Pediatrik(Swepub:umu)kagr0007
(författare)
-
Polychronopoulou, SophiaDepartment of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece
(författare)
-
Rasche, MareikeDepartment of Pediatric Hematology and Oncology, University Hospital Essen, Essen, Germany
(författare)
-
Rubnitz, Jeffrey E.Department of Oncology, St Jude Children's Research Hospital, TN, Memphis, United States
(författare)
-
Stary, JanDepartment of Pediatric Hematology and Oncology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
(författare)
-
Tierens, AnneDepartment of Pathobiology and Laboratory Medicine, Toronto General Hospital, University Health Network, ON, Toronto, Canada
(författare)
-
Tomizawa, DaisukeChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan
(författare)
-
Zwaan, C MichelPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
(författare)
-
Kaspers, Gertjan J LPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
(författare)
-
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Vrije Universiteit Amsterdam, Amsterdam, NetherlandsPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, Netherlands
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of Clinical Oncology: American Society of Clinical Oncology (ASCO)41:16, s. 2963-29740732-183X1527-7755
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
van Weelderen, R ...
-
Klein, Kim
-
Harrison, Christ ...
-
Jiang, Yilin
-
Abrahamsson, Jon ...
-
Arad-Cohen, Nira
-
visa fler...
-
Bart-Delabesse, ...
-
Buldini, Barbara
-
De Moerloose, Ba ...
-
Dworzak, Michael ...
-
Elitzur, Sarah
-
Fernández Navarr ...
-
Gerbing, Robert ...
-
Goemans, Bianca ...
-
de Groot-Krusema ...
-
Guest, Erin
-
Ha, Shau-Yin
-
Hasle, Henrik
-
Kelaidi, Charikl ...
-
Lapillonne, Hélè ...
-
Leverger, Guy
-
Locatelli, Franc ...
-
Masetti, Riccard ...
-
Miyamura, Takako
-
Norén-Nyström, U ...
-
Polychronopoulou ...
-
Rasche, Mareike
-
Rubnitz, Jeffrey ...
-
Stary, Jan
-
Tierens, Anne
-
Tomizawa, Daisuk ...
-
Zwaan, C Michel
-
Kaspers, Gertjan ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Pediatrik
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Umeå universitet